<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02257567</url>
  </required_header>
  <id_info>
    <org_study_id>GO29365</org_study_id>
    <secondary_id>2014-001361-28</secondary_id>
    <nct_id>NCT02257567</nct_id>
  </id_info>
  <brief_title>A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study is a multicenter, open-label study of polatuzumab vedotin administered by
      intravenous (IV) infusion in combination with standard doses of bendamustine (B) and
      rituximab (R) or obinutuzumab (G) in participants with relapsed or refractory follicular
      lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The study comprises two stages: a
      Phase Ib safety run-in stage and a Phase II stage. The anticipated time on treatment is 18
      weeks for participants with DLBCL and 24 weeks for participants with FL.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 15, 2014</start_date>
  <completion_date type="Anticipated">June 13, 2019</completion_date>
  <primary_completion_date type="Actual">April 11, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib: Percentage of Participants with Adverse Events</measure>
    <time_frame>From Baseline until up to 90 days after last dose (up to 36 weeks overall)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Percentage of Participants with Complete Response (CR) According to Modified Lugano Criteria as Measured by Positron Emission Tomography (PET)/Computed Tomography (CT) Scan and Determined by Independent Review Committee (IRC)</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with CR According to Modified Lugano Criteria as Measured by PET/CT Scan and Determined by the Investigator</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with CR or Partial Response (PR) According to Modified Lugano Criteria as Measured by PET/CT Scan and Determined by IRC and Investigator</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with CR According to Modified Lugano Criteria as Measured by CT Scan and Determined by IRC and Investigator</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with CR or PR According to Modified Lugano Criteria as Measured by CT Scan and Determined by IRC and Investigator</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by Best Objective Response (BOR) According to Modified Lugano Criteria as Measured by PET/CT Scan or CT Scan only and Determined by the Investigator</measure>
    <time_frame>Baseline, Cycle 3 Day 15, 6-8 weeks after Cycle 6 Day 1 (cycle length: 21 or 28 days), then every 6 months until progression, withdrawal or study close (up to about 4.5 years overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants with Adverse Events</measure>
    <time_frame>From Baseline until up to 90 days after last dose (up to 36 weeks overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Percentage of Participants with Anti-Drug Antibodies (ADAs) to Polatuzumab in Cohort 1A</measure>
    <time_frame>Pre-dose (0 to 4 hours [h]) on Day 2 of Cycle 1; pre-dose (0 to 4 h) on Day 1 of Cycles 2 and 4; randomly during post-treatment period (up to 2 years overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Percentage of Participants with ADAs to Polatuzumab and Obinutuzumab in Cohort 1B</measure>
    <time_frame>Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4; pre-dose (0 to 4 h) on Day 2 of Cycle 1; randomly during post-treatment period (up to 2 years overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants with ADAs to Polatuzumab in Arms A and C</measure>
    <time_frame>Pre-dose (0 to 4 h) on Day 1 of Cycles 2, 4; pre-dose (0 to 4 h) on Day 2 of Cycle 1; up to 30 days after last dose (approximately 28 weeks); randomly during post-treatment period (up to 2 years overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants with ADAs to Polatuzumab and Obinutuzumab in Arms E and F</measure>
    <time_frame>Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4; pre-dose (0 to 4 h) on Day 2 of Cycle 1; up to 30 days after last dose (approximately 28 weeks); randomly during post-treatment period (up to 2 years overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of Polatuzumab, Bendamustine, and Rituximab in Cohort 1A (milligrams per milliliter [mg/mL])</measure>
    <time_frame>Predose (0 to 4 h), end of infusion (EOI) (Duration of infusion: 90 minutes [1st infusion], 30 minutes [subsequent infusions]) on Day 2, Cycle 1 and Day 1 of Cycles 2,4; Days 8,15 of Cycle 1; randomly during post-treatment period (up to 2 years overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax of Polatuzumab, Bendamustine, and Obinutuzumab in Cohort 1B (mg/mL)</measure>
    <time_frame>Day 1 up to 2 years (detailed timeframe is given in outcome description section)</time_frame>
    <description>Detailed timeframe: Pre-dose (0 to 4 h) on Day 1 of Cycle 1, 2, 4 and Day 2 of Cycle 1; on Days 8, 15 of Cycle 1; at EOI (Duration of infusion: 90 minutes [1st infusion], 30 minutes [subsequent infusions]) on Day 2 of Cycle 1 and Day 1 of Cycles 2, 4; randomly during post-treatment period (up to 2 years overall)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under Concentration-Time Curve (AUC) of Polatuzumab, Bendamustine, and Rituximab in Cohort 1A (hour * milligrams per milliliter [h*mg/mL])</measure>
    <time_frame>Pre-dose (0 to 4 h) and EOI (Duration of infusion:90 minutes [1st infusion], 30 minutes [subsequent infusions]) on Day 2 of Cycle 1 and Day 1 of Cycles 2, 4; on Days 8, 15 of Cycle 1; randomly during post-treatment period (up to 2 years overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC of Polatuzumab, Bendamustine, and Obinutuzumab in Cohort 1B (h*mg/mL)</measure>
    <time_frame>Day 1 up to 2 years (detailed timeframe is given in outcome description section)</time_frame>
    <description>Detailed timeframe: Pre-dose (0 to 4 h) on Day 1 of Cycle 1, 2, 4 and Day 2 of Cycle 1; on Days 8, 15 of Cycle 1; at EOI (Duration of infusion: 90 minutes [1st infusion], 30 minutes [subsequent infusions]) on Day 2 of Cycle 1 and Day 1 of Cycles 2, 4; randomly during post-treatment period (up to 2 years overall)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax of Polatuzumab, Bendamustine, and Rituximab in Arms A and C (mg/mL)</measure>
    <time_frame>Day 1 up to 2 years (detailed timeframe is given in outcome description section)</time_frame>
    <description>Detailed timeframe: Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4; at EOI (Duration of infusion:90 minutes [1st infusion], 30 minutes [subsequent infusions]) on Day 2 of Cycle 1 and Day 1 of Cycles 1, 4; post-dose (1, 2, 3, 4 h) on Day 2 of Cycle 1; after last dose (24 weeks); randomly during post-treatment period (up to 2 years overall)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC of Polatuzumab, Bendamustine, and Rituximab in Arms A and C (h*mg/mL)</measure>
    <time_frame>Day 1 up to 2 years (detailed timeframe is given in outcome description section)</time_frame>
    <description>Detailed timeframe: Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4; at EOI (Duration of infusion: 90 minutes for first infusion and 30 minutes for subsequent infusions) on Day 2 of Cycle 1 and Day 1 of Cycles 1, 4; post-dose (1, 2, 3, 4 h) on Day 2 of Cycle 1; after last dose (24 weeks); randomly during post-treatment period (up to 2 years overall)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax of Bendamustine and Rituximab in Arms B and D (mg/mL)</measure>
    <time_frame>Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4 and Day 2 of Cycle 1; at EOI (Duration of infusion:90 minutes [1st infusion], 30 minutes [subsequent infusions]) on Days 1, 2 of Cycle 1; post-dose (1, 2, 3, 4 h) on Day 2 of Cycle 1 (up to 3 months overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC of Bendamustine and Rituximab in Arms B and D (h*mg/mL)</measure>
    <time_frame>Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4 and Day 2 of Cycle 1; at EOI (Duration of infusion:90 minutes [1st infusion], 30 minutes [subsequent infusions]) on Days 1, 2 of Cycle 1; post-dose (1, 2, 3, 4 h) on Day 2 of Cycle 1 (up to 3 months overall)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax of Polatuzumab, Bendamustine, and Obinutuzumab in Arms E and F (mg/mL)</measure>
    <time_frame>Day 1 up to 2 years (detailed timeframe is given in outcome description section)</time_frame>
    <description>Detailed timeframe: Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4 and Day 2 of Cycle 1; at EOI (Duration of infusion: 90 minutes for first infusion and 30 minutes for subsequent infusions) on Day 2 of Cycle 1 and Day 1 of Cycles 1, 4; post-dose (1, 2, 3, 4 h) Day 2 of Cycle 1; after last dose (24 weeks); randomly during post-treatment period (up to 2 years overall)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC of Polatuzumab, Bendamustine, and Obinutuzumab in Arms E and F (h*mg/mL)</measure>
    <time_frame>Day 1 up to 2 years (detailed timeframe is given in outcome description section)</time_frame>
    <description>Detailed timeframe: Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4 and Day 2 of Cycle 1; at EOI (Duration of infusion: 90 minutes for first infusion and 30 minutes for subsequent infusions) on Day 2 of Cycle 1 and Day 1 of Cycles 1, 4; post-dose (1, 2, 3, 4 h) Day 2 of Cycle 1; after last dose (24 weeks); randomly during post-treatment period (up to 2 years overall)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS)</measure>
    <time_frame>Every week during treatment (up to 24 weeks) and for the first 2 months after treatment, thereafter every month for 10 months or until withdrawal (up to 18 months overall)</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A (Phase II Randomization): Polatuzumab+BR in FL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Phase II Randomization): BR in FL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with FL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (Phase II Randomization): BR in DLBCL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with DLBCL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E (Phase II Expansion): Polatuzumab+BG in FL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).</description>
    <arm_group_label>Arm A (Phase II Randomization): Polatuzumab+BR in FL</arm_group_label>
    <arm_group_label>Arm B (Phase II Randomization): BR in FL</arm_group_label>
    <arm_group_label>Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Arm D (Phase II Randomization): BR in DLBCL</arm_group_label>
    <arm_group_label>Arm E (Phase II Expansion): Polatuzumab+BG in FL</arm_group_label>
    <arm_group_label>Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL</arm_group_label>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL</arm_group_label>
    <other_name>Treanda; Ribomustin; Levact</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).</description>
    <arm_group_label>Arm E (Phase II Expansion): Polatuzumab+BG in FL</arm_group_label>
    <arm_group_label>Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL</arm_group_label>
    <other_name>GA101; Gazyva; Gazyvaro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polatuzumab vedotin</intervention_name>
    <description>Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).</description>
    <arm_group_label>Arm A (Phase II Randomization): Polatuzumab+BR in FL</arm_group_label>
    <arm_group_label>Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Arm E (Phase II Expansion): Polatuzumab+BG in FL</arm_group_label>
    <arm_group_label>Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL</arm_group_label>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL</arm_group_label>
    <other_name>DCDS4501A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).</description>
    <arm_group_label>Arm A (Phase II Randomization): Polatuzumab+BR in FL</arm_group_label>
    <arm_group_label>Arm B (Phase II Randomization): BR in FL</arm_group_label>
    <arm_group_label>Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Arm D (Phase II Randomization): BR in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL</arm_group_label>
    <other_name>Rituxan; MabThera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed relapsed or refractory FL (Grades 1, 2, or 3a) or relapsed or
             refractory DLBCL

          -  If the participant has received prior bendamustine, response duration must have been
             greater than (&gt;) 1 year (for participants who have relapse disease after a prior
             regimen)

          -  At least one bi-dimensionally measurable lesion on imaging scan defined as &gt;1.5
             centimeters (cm) in its longest dimension

          -  Confirmed availability of archival or freshly collected tumor tissue

          -  Life expectancy of at least 24 weeks

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          -  Adequate hematological function unless inadequate function is due to underlying
             disease

        Exclusion Criteria:

          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
             antibodies (MAbs, or recombinant antibody-related fusion proteins) or known
             sensitivity or allergy to murine products

          -  Contraindication to bendamustine, rituximab, or obinutuzumab

          -  Prior use of any MAb, radioimmunoconjugate, or antibody-drug conjugate (ADC) within 4
             weeks or 5 half-lives before Cycle 1 Day 1

          -  Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy,
             or any investigational agent for the purposes of treating cancer within 2 weeks prior
             to Cycle 1 Day 1

          -  Ongoing corticosteroid use &gt;30 mg per day prednisone or equivalent, for purposes other
             than lymphoma symptom control

          -  Completion of autologous stem cell transplant (SCT) within 100 days prior to Cycle 1
             Day 1

          -  Prior allogeneic SCT

          -  Eligibility for autologous SCT

          -  Grade 3b FL

          -  History of transformation of indolent disease to DLBCL

          -  Primary or secondary CNS lymphoma

          -  Current Grade &gt;1 peripheral neuropathy

          -  Evidence of significant, uncontrolled concomitant diseases that could affect
             compliance with the protocol or interpretation of results, including significant
             cardiovascular disease (such as New York Heart Association Class III or IV cardiac
             disease, myocardial infarction within the last 6 months, unstable arrhythmias, or
             unstable angina) or significant pulmonary disease (including obstructive pulmonary
             disease and history of bronchospasm)

          -  Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection
             (excluding fungal infections of nail beds) at study enrollment or any major episode of
             infection requiring treatment with IV antibiotics or hospitalization within 4 weeks
             prior to Cycle 1 Day 1

          -  Suspected or latent tuberculosis

          -  Positive test results for chronic hepatitis B virus (HBV) infection or for hepatitis C
             virus (HCV) antibody

          -  Known history of human immunodeficiency virus (HIV) seropositive status or known
             infection with human T-cell leukemia virus 1 (HTLV-1) virus

          -  Women who are pregnant or lactating or who intend to become pregnant within a year of
             the last dose of study treatment in the rituximab cohort or within 18 months of last
             dose in the obinutuzumab cohort

          -  Evidence of laboratory abnormalities in standard renal, hepatic, or coagulation
             function tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clearview Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Canc Ctr</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Univ Winship Cancer Inst</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology-Hematology; Associates, Ltd.</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Research, Inc.</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weinberg CA Inst Franklin Sq</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates LLC - Morristown</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan Oncology Associates</name>
      <address>
        <city>Farmington</city>
        <state>New Mexico</state>
        <zip>87401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Inst.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital; Oncology</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adelaide Cancer Centre</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre; Haematology Research</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA-Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre; Oncology</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve- Rosemont; Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno; Interni hematoonkologicka klinika</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Ostrava Klinika hematoonkologie</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I Interni klinika; Vseobecna fakultni nemocnice</name>
      <address>
        <city>Prague 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Site Du Bocage;Hematologie Clinique</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental Les Oudairies</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard; Departement Oncologie Medicale</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut J Paolii Calmettes; Onco Hematologie 1</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Eloi; Service d'Hématologie Clinique</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU NANTES - Hôtel Dieu; Service d'Hematologie Clinique</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud - Service Hématologie</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel; Hematologie</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Erfurt - Innere Medizin - 4. Medizinische Klinik, Hämatologie</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald; Innere Medizin C, Hämatologie/Onkologie</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Abt. für Hämatologie und Onkologie</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mühlenkreiskliniken; Johannes Wesling Klinikum Minden; Klinik für Hämatologie, Onkologie und Pallia.</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik der Uni Regensburg; Hämatologie/Onkologie, Studienzentrale</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, First Dept of Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology, A Dept of Internal Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen Medical and Health Science Center, Institute of Internal medicine Building B</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ist.Naz.Le Tumori Fond;Pascale Napoli; Farmacia</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Europeo Di Oncologia (IEO); Emato-Oncologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile SS. Antonio E Biagio DI Alessandria; Ematologia</name>
      <address>
        <city>Alessandria</city>
        <state>Piemonte</state>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG - Groningen; Hematology</name>
      <address>
        <city>Groningen</city>
        <zip>9712 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud; Hematology</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VUMC</name>
      <address>
        <city>NL -amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona; Hematology</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Paz; Servicio de Hematologia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca;Servicio de Hematologia</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio; Servicio de Hematologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara University; Hematology</name>
      <address>
        <city>Ankara</city>
        <zip>06620</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul Uni ; Hematology</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ondokuzmayis University Medical Faculty Heamatology Department</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karadeniz Technical Uni School of Medicine; Hematology</name>
      <address>
        <city>Trabzon</city>
        <zip>61800</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital Nhs Trust; Medical Oncology</name>
      <address>
        <city>Manchester</city>
        <zip>M2O 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital; Dept of Haematology</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital; Somers Cancer Research Building</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2014</study_first_submitted>
  <study_first_submitted_qc>October 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2014</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

